Â鶹ӳ»­

MD Anderson Cancer Center was awarded more than $22 million in research grants in November from the (CPRIT). Thirty-six percent of funds awarded for Individual Investigator Awards (IIA) went to MD Anderson faculty members as well as nearly 40% of funds awarded for recruitment, reflecting the excellence and impact of the institution¡¯s world-class cancer researchers and star recruitment candidates.

Across Texas institutions, CPRIT awarded a total of $112 million in 73 new grants. MD Anderson CPRIT awards included $14.8 million for research, $6 million in recruitment funding and $1.4 million for evidence-based cancer prevention services. Consistent with MD Anderson¡¯s broad research program, these CPRIT awards will fund exciting studies in cancers of the liver, skin, pancreas, and ovary, as well as lymphoma, leukemia and other cancers. A full listing of individual awards can be found below.

MD Anderson awards include the following:

• Amplified gold nanoparticle-mediated radiosensitization of tumors ¡ª $899,309
• Imaging-based quantitative analysis of vascular perfusion and tissue oxygenation to improve therapy of hepatocellular carcinoma ¡ª $885,901
• Understanding biological and physical factors affecting response to proton therapy to improve clinical effectiveness ¡ª $879,362
• Exploiting molecular and metabolic dependencies to optimize personalized therapeutic approaches for melanoma ¡ª $900,000
• Mechanisms and targeting strategies for SWI/SNF mutations in cancer ¡ª $900,000
• Visualizing T-cell trafficking ¡ª $900,000
• An adaptive personalized clinical trial using a patient-derived xenograft strategy to overcome ibrutinib resistance in cell lymphoma ¡ª $841,606
• Investigating the genetic and molecular mechanisms underlying RAS/ERK substrate network ¡ª $900,000
• Regulation of infiltration and function of tumor-resident CD8 T-cells by IL-15 ¡ª $828,060
• Exosomal DNA as a surrogate biomarker for early diagnosis and therapeutic stratification in pancreatic cancer ¡ª $891,938
• Nanoparticle targeted STAT3 immune expression ¡ª $888,429
• Clinical safety and efficacy of third-party, fucosylated cord blood-derived regular T-cells to prevent graft versus host disease ¡ª $900,000
• Radiogenomic screen to identify novel proliferation associated glioblastoma genomic therapeutic targets: discovery and mechanistic validation study ¡ª $897,627
• Identifying new epigenetic vulnerabilities in pancreatic cancer ¡ª $900,000